Revolution Medicines
Revolution Medicines reported revenue of $0 million in fiscal 2025. Free cash flow was −$914 million. The diluted share count rose 13.3%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Revolution Medicines lost money in fiscal 2025: a net loss of $1.1 billion.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 577 | 645 | 1,853 | 2,289 | 2,026 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −15,667.3x | — | — | — | −48.8x |
| Current ratio | 9.8x | 10.7x | 13.1x | 14.2x | 7.1x |
| Quick ratio | 9.8x | 10.7x | 13.1x | 14.2x | 7.1x |
Cash flow
Projections
Project Revolution Medicines' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Revolution Medicines shares on the open market, and 12 insiders sold $151.0 million, $150.2 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Stephen Michael KelseySee Remarks | Sold plan | 27,160 | $167.86 | $4.6 million | Form 4 |
| Sep 25, 2026 | Anthony ManciniSee Remarks | Sold plan | 3,121 | $200.54 | $625,885 | Form 4 |
| Sep 25, 2026 | Jeff CisliniSVP & General Counsel | Sold plan | 765 | $207.32 | $158,600 | Form 4 |
| Sep 24, 2026 | Anthony ManciniSee Remarks | Sold plan | 587 | $200.00 | $117,400 | Form 4 |
| Sep 22, 2026 | Elizabeth M AndersonDirector | Sold plan | 10,143 | $193.04 | $2.0 million | Form 4 |
| Sep 18, 2026 | Anthony ManciniSee Remarks | Sold plan | 1,764 | $196.94 | $347,402 | Form 4 |
| Sep 16, 2026 | Mark A GoldsmithSee Remarks, Director | Sold plan | 13,988 | $199.23 | $2.8 million | Form 4 |
| Sep 16, 2026 | Stephen Michael KelseySee Remarks | Sold plan | 5,569 | $199.23 | $1.1 million | Form 4 |
| Sep 16, 2026 | Margaret A HornChief Operating Officer | Sold plan | 4,967 | $199.23 | $989,597 | Form 4 |
| Sep 16, 2026 | Jack AndersChief Financial Officer | Sold plan | 4,053 | $199.24 | $807,501 | Form 4 |
| Sep 16, 2026 | Jeff CisliniSVP & General Counsel | Sold plan | 3,366 | $199.23 | $670,621 | Form 4 |
| Sep 16, 2026 | Anthony ManciniSee Remarks | Sold plan | 1,774 | $199.24 | $353,443 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −3,161.4% | — | — |
| Altman Z'' | 10.28 | 9.64 | −0.01 |
| Accruals ratio | −6.0% | −1.9% | −9.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Revolution Medicines side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Revolution Medicines | FY25 | — | — | — | — | — | — | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 20 | 50 | 43 | 29 | 35 | 12 | 0 | 0 |
| Revenue growth | — | 148.2% | −14.1% | −31.6% | 20.4% | −67.3% | −100.0% | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | 51 | 92 | 132 | 187 | 253 | 423 | 592 | 987 |
| Operating income | −40 | −54 | −111 | −188 | −258 | −487 | −690 | −1,182 |
| Net income | −42 | −48 | −108 | −187 | −249 | −436 | −600 | −1,131 |
| Diluted EPS (US$) | −21.24 | −22.33 | −2.01 | −2.57 | −3.08 | −3.86 | −3.58 | −5.95 |
| Diluted shares (millions) | 2 | 3 | 55 | 73 | 81 | 113 | 168 | 190 |
| Cash flow | ||||||||
| Cash from operations | 1 | −50 | −100 | −147 | −224 | −351 | −557 | −898 |
| Capital expenditure | 2 | 3 | 3 | 6 | 11 | 8 | 10 | 16 |
| Free cash flow | −0 | −52 | −103 | −154 | −235 | −358 | −568 | −914 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 3 | 9 | 21 | 31 | 62 | 79 | 118 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 70 | 123 | 441 | 577 | 645 | 1,853 | 2,289 | 2,026 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | — | 220 | 567 | 738 | 812 | 2,062 | 2,558 | 2,354 |
| Total liabilities | — | 68 | 93 | 135 | 127 | 236 | 293 | 723 |
| Shareholders' equity | −108 | −153 | 475 | 603 | 685 | 1,826 | 2,265 | 1,631 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | −200.0% | −108.2% | −257.5% | −639.7% | −730.0% | −4,207.1% | — | — |
| Net margin | −207.2% | −95.2% | −251.6% | −636.6% | −703.0% | −3,768.3% | — | — |
| Free cash flow margin | −1.4% | −104.3% | −239.6% | −523.0% | −664.8% | −3,094.1% | — | — |
| Rule of 40 (growth + FCF margin) | — | 43.8% | −253.7% | −554.6% | −644.5% | −3,161.4% | — | — |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −67.2% | −34.7% | −38.6% | −34.8% | −29.3% | −58.1% |
| Return on assets | — | — | −27.4% | −28.7% | −32.1% | −30.4% | −26.0% | −46.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |